WBA - Widely Popular GLP-1-Based Weight Loss Drugs Reshape US Healthcare Landscape May Help Control Addiction | Benzinga
Speakers at an event highlighted the impact of a new class of weight loss drugs, including substance abuse, on the U.S. healthcare system.
Wednesday, the FDA approved Eli Lilly And Co's (NYSE: LLY) Zepbound (tirzepatide) injection for obesity treatment.
Novo Nordisk A/S (NYSE: NVO) entered the arena with Wegovy, or semaglutide, approved for obesity in 2021 and sold as Ozempic for diabetes.
Zepbound has a list price of $1,059.87, approximately 20% lower than Novo Nordisk's ...